ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2020-02-12 07:27 (390 d 23:18 ago) – Posting: # 21162
Views: 3,729

Hi MS,

» Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;

Ermmm...... WHAT???? :-D:party:

Pass or fail!

Complete thread:

 Admin contact
21,372 posts in 4,463 threads, 1,496 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).
Forum time: Tuesday 06:45 UTC (Europe/Vienna)

We learn more by looking for the answer to a question and not finding it
than we do from learning the answer itself.    Lloyd Alexander

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz